Drug General Information
Drug ID
D0J6AU
Former ID
DCL000568
Drug Name
Odanacatib
Synonyms
Odanacatib; MK 0822; MK0822; MK-0822A; Odanacatib (USAN)
Drug Type
Small molecular drug
Indication Ostereoporosis [ICD9: 733; ICD10:M80-M81] Phase 1 [548318]
Company
Merck
Structure
Download
2D MOL

3D MOL

Formula
C25H27F4N3O3S
Canonical SMILES
CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)<br />S(=O)(=O)C)C(F)(F)F)F
InChI
1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
InChIKey
FWIVDMJALNEADT-SFTDATJTSA-N
CAS Number
CAS 603139-19-1Topotecan
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Cathepsin K Target Info Inhibitor [536569], [549718]
KEGG Pathway Lysosome
Osteoclast differentiation
Toll-like receptor signaling pathway
Rheumatoid arthritis
NetPath Pathway TGF_beta_Receptor Signaling Pathway
RANKL Signaling Pathway
IL2 Signaling Pathway
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
Trafficking and processing of endosomal TLR
MHC class II antigen presentation
WikiPathways RANKL/RANK Signaling Pathway
Osteoclast Signaling
References
Ref 548318Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024552)
Ref 536569Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008 Jan;83(1):172-6. Epub 2007 Dec 12.
Ref 549718A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.